Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study-Reference-Cited by-同舟云学术

Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study

Published:2022-08-17 Issue:6 Volume:23 Page:891-904
ISSN:1175-0561
Container-title:American Journal of Clinical Dermatology
language:en
Short-container-title:Am J Clin Dermatol

Author:

Torres Tiago^ORCID,Puig Luis,Vender Ron,Yeung Jensen,Carrascosa José-Manuel,Piaserico Stefano,Gisondi Paolo,Lynde Charles,Ferreira Paulo,Bastos Pedro Mendes,Dauden Esteban,Leite Luiz,Valerio Joana,del Alcázar-Viladomiu Elena,Rull Eva Vilarrasa,Llamas-Velasco Mar,Pirro Federico,Messina Francesco,Bruni Manfredo,Licata Gaetano,Ricceri Federica,Nidegger Alessia,Hugo Jan,Mufti Asfandyar,Daponte Athina-Ioanna,Teixeira Laetitia,Balato Anna,Romanelli Marco,Prignano Francesca,Gkalpakiotis Spyridon,Conrad Curdin,Lazaridou Elizabeth,Rompoti Natalia,Papoutsaki Marina,Nogueira Miguel,Chiricozzi Andrea

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40257-022-00722-y.pdf

Reference22 articles.

1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–60. https://doi.org/10.1001/JAMA.2020.4006.

2. Tsai Y-C, Tsai T-F. Switching biologics in psoriasis—practical guidance and evidence to support. Expert Rev Clin Pharmacol. 2020;13(5):493–503. https://doi.org/10.1080/17512433.2020.1767590.

3. Costanzo A, Malara G, Pelucchi C, et al. Effectiveness end points in real-world studies on biological therapies in psoriasis: systematic review with focus on drug survival. Dermatology. 2018;234(1–2):1–12. https://doi.org/10.1159/000488586.

4. van den Reek JMPA, Kievit W, Gniadecki R, et al. Drug survival studies in dermatology: principles, purposes, and pitfalls. J Investig Dermatol. 2015;135(7):1–5. https://doi.org/10.1038/JID.2015.171.

5. Torres T, Puig L, Vender R, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567–79. https://doi.org/10.1007/S40257-021-00598-4.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug survival of interleukin 17 inhibitors after switch from interleukin 23 inhibitors in psoriasis: An observational cohort study;Journal of the American Academy of Dermatology;2024-09

2. Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia;Journal of Dermatological Treatment;2024-08-05

3. Long-term quality of life outcomes from a phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis in a real-world setting;Journal of Dermatological Treatment;2024-07-22

4. Psoriatic arthritis, biologic therapy experience, body mass index, and onset age of psoriasis were independent factors of secukinumab discontinuation in patients with psoriasis;Expert Review of Clinical Pharmacology;2024-07-12

5. Reflectance confocal microscopy for plaque psoriasis therapeutic follow-up during an anti-interleukin-17A monoclonal antibody: an observational study;Scientific Reports;2024-07-02